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a b s t r a c t
Evidence suggests that multiple genetic and environmental factors conspire together to increase sus-
ceptibility to Alzheimer’s disease (AD). The amyloid cascade hypothesis states that deposition of the
amyloid-b (Ab) peptide is central to AD; however, evidence in humans and animals suggests that Ab
buildup alone is not sufﬁcient to cause neuronal cell loss and cognitive decline. Mousemodels that express
high levels of mutant forms of amyloid precursor protein and/or cleaving enzymes deposit amyloid but do
not show neuron loss. Therefore, a double-hit hypothesis for AD has been proposed whereby vascular
dysfunction precedes and promotes Ab toxicity. In support of this, copy number variations inmesenchyme
homeobox 2 (MEOX2), a gene involved in vascular development, are associated with severe forms of AD.
However, the role of MEOX2 in AD has not been studied. Here, we tested Meox2 haploinsufﬁciency in
B6.APP/PS1 (B6.APBTg) mice, amousemodel of AD. Despite no overt differences in plaque deposition or glial
activation, B6.APBTgmice that carry only one copy ofMeox2 (B6.APBTg.Mx/þ) show increased neuronal cell
loss, particularly in regions containing plaques, compared with B6.APBTg mice. Neuronal cell loss corre-
sponds with a signiﬁcant decrease in plaque-associated microvessels, further supporting a synergistic
effect of vascular compromise and amyloid deposition on neuronal cell dysfunction in AD.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Alzheimer’s disease (AD), a leading cause of dementia, is a
complex disease characterized by severe cognitive deﬁcits,
neuronal loss, and ultimately death. Accumulation of amyloid-b
(Ab) peptide and plaque deposition in the brain and blood vessel
walls are distinctive features of AD that are likely to occur in part as
a consequence of neurovascular breakdown (Zlokovic, 2011).
Recent evidence supports a signiﬁcant role of cerebrovascular
dysfunction in AD pathogenesis, including severe brain microvas-
cular pathology, angiogenesis impairment, deﬁcits in Ab peptide
clearance through the blood brain barrier (BBB), and cerebral am-
yloid angiopathy (Brown and Thore, 2011; Farkas and Luiten, 2001;
Grammas, 2011; Zlokovic, 2011). In addition, it is known that
vascular risk factors such as diabetes, hypertension, obesity, and
cardiovascular disease predispose individuals to AD (Dewey and
Saz, 2001; Knopman and Roberts, 2010; Norton et al., 2014),
possibly by decreasing cerebral blood ﬂow (CBF) and promoting
hypoperfusion-hypoxia in the brain (Brown and Thore, 2011; Farkas
and Luiten, 2001; Grammas, 2011; Zlokovic, 2011). More impor-
tantly, in vivo imaging studies in humans have demonstrated that
early cerebrovascular hypoperfusion precedes Ab accumulation and
brain atrophy in AD and is associated with cognitive decline
(Iadecola, 2004; Knopman and Roberts, 2010; Zlokovic, 2011),
suggesting that early neurovascular pathology and dysfunction lead
to neuronal failure and neurodegeneration.
In recent years, increasing evidence in animal models and hu-
man brains from AD patients have demonstrated how molecular
and cellular events that lead to neurovascular dysfunction inﬂuence
and interact with other pathologic processes in AD, including Ab
accumulation and tau pathology (Halliday et al., 2015; Sagare et al.,
2013; Sengillo et al., 2013; Winkler et al., 2015; Zhao et al., 2015). It
has been found that genetically induced loss of pericytes in amyloid
precursor protein (APP)-overexpressing mice causes BBB break-
down, increased levels of Ab plaque deposition, and extensive loss
of neurons (Sagare et al., 2013). In addition, extensive loss of
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pericytes and BBB breakdown were evident in human brains from
AD patients carrying the apolipoprotein E4 (APOE4) gene (Halliday
et al., 2015). Also, reduced expression of PICALM, a genetic risk
factor for AD, is associated with reductions in clearance of Ab and
cognitive impairments (Zhao et al., 2015). More recently, it was
found that genetic reduction of the glucose transporter GLUT1 in
brain endothelial cells from mice overexpressing APP caused BBB
breakdown, increased levels of Ab plaque deposition, and signiﬁ-
cant neuronal loss (Winkler et al., 2015). Collectively, these studies
strongly support an early and signiﬁcant role of neurovascular
disruption in AD onset and progression. In line with these ﬁndings,
a two-hit vascular hypothesis has been proposed, postulating that
vascular risk factors (that are increased by age) induce BBB break-
down and/or hypoperfusion, thus disrupting Ab clearance and
neurotoxicity (Zlokovic, 2011). Ab deposition may also amplify the
neurovascular injury by disrupting angiogenic responses in brain
endothelial cells and promoting blood vessel elimination, leading to
neuronal dysfunction and neurodegeneration (Brown and Thore,
2011; Grammas et al., 2011).
Genetic risk factors are important contributors to AD develop-
ment. A recent genome-wide association study identiﬁed rare copy
number variations associated with early and severe phenotypes of
AD (Rovelet-Lecrux et al., 2012). The study identiﬁed copy number
variations in the homeobox protein mesenchyme homeobox 2
(MEOX2), a gene expressed by the vascular system that plays a
major role in vascular differentiation (Gorski and Walsh, 2003).
MEOX2 expression is downregulated in brain endothelial cells from
AD patients, and reduced levels of MEOX2 cause aberrant angio-
genic responses in human and mouse endothelial cells (Wu et al.,
2005). However, the impact of Meox2 haploinsufﬁciency in mouse
models of AD remains to be tested.
As copy number variations in MEOX2 are associated with early
and severe phenotypes of AD, in this study, the contribution of
Meox2 haploinsufﬁciency (i.e., one copy of Meox2) to AD pathology
in C57BL/6J.APPswePSEN1de9 (Jankowsky et al., 2004, herein referred
to as B6.APBTg) mice was assessed. B6.APBTg mice haploinsufﬁcient
for Meox2 presented signiﬁcant neuronal degeneration and cogni-
tive decline that correlated with a loss of microvessels, particularly
in regions of Ab plaque deposition. This suggests that Meox2 hap-
loinsufﬁciency may sensitize endothelial cells to Ab toxicity and
further supports a contribution of vascular dysfunction to AD sus-
ceptibility and pathology.
2. Materials and methods
2.1. Mouse strains and cohort generation
All experiments involving mice were conducted in accordance
with policies and procedures described in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health
and were approved by the Institutional Animal Care and Use
Committee at The Jackson Laboratory. All mice were bred and
housed in a 12/12 hour light/dark cycle. All experiments were
performed on a uniﬁed genetic background (C57BL/6J). C57BL/6J
mice heterozygous for the insertion of the cre-recombinase gene in
place of theMeox2 genewere obtained fromThe Jackson Laboratory
(B6.129S4-Meox2CreSor, JAX stock #003755). The Cre insertion ab-
lates the transcription of the Meox2 gene creating a Meox2 null
allele (Mx/þ). C57BL/6J.APPswePsen1de9 mice (B6.Cg-Tg(APPswe,
PSEN1dE9)85Dbo/Mmjax, JAX stock #005864), referred to in this
study as B6.APBTg mice, were obtained from the Mutant Mouse
Resource and Research Center at The Jackson Laboratory.
To produce experimental animals, Mx/þ mice were crossed
with B6.APBTg mice and aged. For the Y-maze task, cohorts of 8e10
mice for each of the 4 genotypes were established and aged to
14 months. For postmortem characterization of AD phenotypes,
brains from 2 males and 2 females at 10 and 14 months (a total of 8
mice per genotype, 32 mice in total) were assessed. Mouse brains
were also examined at 4 months of age to determine early changes
in microvascular density because of Meox2 haploinsufﬁciency.
Although disease onset and early progression are greater in female
B6.APBTg mice, in our colony, no differences in AD phenotypes are
observed at these later ages (10 and 14 months). Therefore, data
from male and female mice were combined.
2.2. Spatial working memory tests using the Y-maze
Behavioral tests were performed in the Mouse Neuro-
phenotyping Behavioral Facility at The Jackson Laboratory. To test
spatial working memory, spontaneous alternation behavior was
assessed using the Y-maze test. Each group of mice was compared
with theother experimental/control groups andalso to chance levels
(50%) as reported by others (Bertholet and Crusio, 1991; Hooper
et al., 1996; Jacquelin et al., 2012). At the beginning of trials, mice
were placed midway in the start arm and allowed to freely explore
the 3 arms for 8 minutes. The sequence of arm entries was recorded
by a ceiling-mounted video camera and analyzed with Ethovision
software (Noldus). Themazewas cleaned with 1% Virkon before the
tests began and between animals to eliminate traces of odor. The
number of arm entries and the number of triads (deﬁned as entries
into the 3 different arms of the Y-maze without returning to a pre-
viously visited arm, Drew et al., 1973; Hughes, 2004) were recorded
to calculate the alternation percentage. Only mice that performed
>20armentrieswere included in theanalysis, toensure that animals
were engaged in active exploration of the maze.
2.3. Tissue harvesting, protein isolation, and sectioning
Mice were administered a lethal dose of ketamine/xylazine by
intraperitoneal injection, in accordance to Institutional Animal Care
and Use Committee protocols, and transcardially perfused with 1
phosphate-buffered saline (PBS) at 4, 10, and 14 months of age.
Brainswere thendissected, the righthemispherewas snap frozen for
protein isolation, and the left hemisphere was ﬁxed in 4% para-
formaldehyde overnight at 4 C, rinsed with 1 PBS, cryoprotected
ﬁrst in 10% and then in 30% sucrose at 4 C, and embedded in optimal
cutting temperature compound. Frozen brains were sectioned at
20 mm and stored at 80 C until required. Protein (for 6E10 and
human Ab42 measurements) was extractedwith Trizol Reagent (Life
Technologies cat#15596e018) followingmanufacturer’s guidelines.
Pelletswere resuspended in a solution of 1:18Murea and 1% sodium
dodecyl sulfate. Additional samples were extracted via RIPA lysis
buffer (Sigma-Aldrich) for MEOX2Western blots.
2.4. Immunoﬂuorescence and Thioﬂavin S staining
Brain sections were incubated 2 nights at 4 C in the following
primary antibodies: goat polyclonal anti-CD31 (1:40; R&D Systems),
Biotinylated Lycoperiscon Esculentum (Tomato) Lectin (1:200;
Vector), chicken polyclonal anti-glial ﬁbrillary acidic protein (GFAP)
(1:200; Acris Antibodies), rabbit polyclonal anti-IBA1 (also known
as allograft inﬂammatory factor [AIF1]) (1:200; Wako), rat mono-
clonal CD68 (1:200; AbD Serotec), sheep polyclonal TREM2 (1:100;
R&D Systems), laminin A2 (LAMA2) (1:100; Abcam), andmouse anti
NEUN (1:200; Millipore). All antibodies were diluted in 1 PBS and
1% TritonX-100 containing 10% normal donkey serum. After primary
incubation, sections werewashed 3 times in 1 PBS and 1% TritonX-
100 and incubated with their respective secondary antibody
(donkey anti-chicken Alexa Fluor 633, donkey anti-rabbit Alexa
Fluor 488/594, donkey anti-goat Alexa Fluor 488/594, donkey
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anti-rat Alexa Fluor 594, donkey anti-mouse Alexa Fluor 488/633,
Streptavidin Alexa 488/633,1:1000 dilution; Life Technologies) for 2
hours at room temperature. All sections were then counterstained
with 4’,6-diamidino-2-phenylindole and mounted with Aqua Poly-
Mount. For Thioﬂavin S staining, sections stained with antibodies
raised against IBA1 and GFAP or lectin were further counterstained
with 1% Thioﬂavin S (diluted in a 1:1 water:ethanol ratio). Slides
were incubated for 8 minutes at room temperature in 1% Thioﬂavin
S, washed in 80% ethanol, then in 95% ethanol, and ﬁnally in dH2O,
andmounted. Imageswere taken using either the Leica SP5 confocal
microscope or the Zeiss Axio Imager Z2, located within the
Imaging facility at The Jackson Laboratory.
2.5. Image quantitative analyses
Quantiﬁcations were performed as follows. For plaque counts,
the number of plaques present in the entire cortical region from a
central section for each mouse was determined. For quantiﬁcation
of IBA1þ cells in the cortex, 4 images (20, 1388  1040 microns)
were taken for each brain from each mouse with a Zeiss Axio
Imager ﬂuorescent microscope, and cells were manually counted
using the cell counter plugin from ImageJ (1.47 d) software. For
counting NEUNþ cells in the cortex, 4 images (20, 1388  1040
microns) were randomly taken in similar areas for each brain from
eachmouse and cropped to 209.63114.17microns (including only
cortical layers II and III). For quantiﬁcation of pyramidal neurons in
the hippocampus, images of the CA1 region were taken at 63.
NEUNþ cells in the cortex and hippocampus images were manually
counted with the cell counter plugin from ImageJ (1.47 d) software.
All image analyses were performed blind to the experimental
conditions. For IBA1þ cells, 3 equally spaced images were captured
(using 20 optical lens) of the cortex from a central section of each
mouse. For IBA1þ cells surrounding plaques, 6 plaque regions per
brainwere imaged (using 20 optical lens). Images were processed
and cells counted using the cell counter plugin for ImageJ/FIJI. Cells
from the 3 images from eachmousewere totaled and then averaged
across mice. For the analysis of structures surrounding plaques (i.e.,
CD31þ microvessels, NEUNþ neurons, lectinþ, or IBA1þ clusters),
images were taken speciﬁcally in regions of the cortex that con-
tained plaques in B6.APBTg and B6.APBTg.Mx/þ brains. Each image
was cropped (171.5  159.9 microns) to center on a plaque
(to minimize the area within the image not containing plaque).
Fig. 1. Haploinsufﬁciency of Meox2 expression causes reduction in microvascular density. (A) Western blot analysis showing a signiﬁcant reduction (48%) of MEOX2 protein in
B6.Mx/þ mice. (B) Representative images and quantitative analysis of CD31 immunostaining in the cortex of B6 and B6.Mx/þmice at 4 months of age, demonstrating a signiﬁcant
reduction in microvascular density. (C) Representative images and quantitative analysis of NEUN immunostaining in the cortex of B6 and B6.Mx/þ mice at 10 months of age. No
changes in the number of neurons were found between groups. (AeC) Values are relative mean  standard error of the mean to the B6 values, n ¼ 4 mice per group, *p ¼ 0.0406, and
***p ¼ 0.0008 by unpaired t test. Scale bars: 50 mm.
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Neuron (NEUNþ), microvessel (LAMA2), and plaque/microvessel
(lectin) areawere calculated separately. As the lectin area contained
plaque and microvessel area, plaque area alone was calculated as
lectin area e LAMA2 area. In all cases, area was calculated using
specially designed algorithms that have been described and vali-
dated previously (Soto et al., 2015) and are available on request.
2.6. Western blotting
Protein levels of human APP in transgenic mice were measured
using Western blotting. Protein sample concentration was
determined via DC assay (Bio-Rad), and a total of 1.5 mg of the
proteinwas used for this analysis. Samples were heated to 95 C for
5 minutes and then loaded onto a 12% TGX stain-free gel (Bio-Rad).
Gels were run at 150 V for 45 minutes and then transferred to a
nitrocellulose membrane (Life Technologies) via the iBlot for 7
minutes. Blots were then incubated for 2 nights to a blocking so-
lution (5% skim milk powder block in 0.1% PBS-Tween) with 6E10
antibody (1:2000, Covance/BioLegend) or Meox2 (1:1000) at 4 C.
Blots were thenwashed 3 times in 0.1% PBS-Tween and incubated in
the appropriate secondary antibody (anti-mouse IgG 1:30,000;
Millipore) for 2 hours at room temperature. Detection was carried
Fig. 2. Y-maze deﬁcits and neuronal cell loss in B6.APBTg.Mx/þmice. (A) Y-maze spontaneous alternation test shows signiﬁcant deﬁcits in percentage of alternation in B6.APBTg.Mx/þ
mice compared with B6, B6.Mx/þ, and B6.APBTg mice at 14 months of age. (B) No signiﬁcant differences in the number of entries during the test were found between the groups. (C)
Representative images of NEUN immunostaining in the cortex of B6, B6.APBTg, B6.Mx/þ, and B6.APBTg.Mx/þmice at 14 months of age. (D) Representative images of NEUN immuno-
staining in the hippocampal CA1 of B6, B6.APBTg, B6.Mx/þ, and B6.APBTg.Mx/þmice at 14months of age. (E) Quantitative analysis of NEUN-immunostained neurons in the cortexof B6,
B6.APBTg, B6.Mx/þ, and B6.APBTg.Mx/þmice at 14months of age, showing a signiﬁcant decrease of neurons in B6.APBTg.Mx/þmice. (F) In the hippocampal CA1, quantitative analysis of
NEUNþneurons showsa signiﬁcantdecrease inB6.APBTg andB6.APBTg.Mx/þmice, comparedwithB6andB6.Mx/þmice.However, there is also a signiﬁcant decrease inNEUNþneurons
inB6.APBTg.Mx/þmice comparedwithB6.APBTgmice. (A andB)n¼8mice per group. (E andF)n¼4miceper group. (A andB) and (E and F)Values aremean standarderrorof themean.
*p < 0.05, **p ¼ 0.001, and ****p < 0.0001 by 1-way analysis of variance. Scale bars: 50 mm.
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out using ECL detection reagents (GE Healthcare). Blots were
treated with 0.25% sodium azide, thoroughly washed, further pro-
bed with anti-beta actin (1:1000; Abcam) in 0.1% PBS-Tween
overnight at 4 C, washed 3 times, incubated with secondary anti-
body (anti-mouse IgG 1:30,000; Millipore) for 2 hours at room
temperature, washed, and detected.
2.7. Enzyme-linked immunosorbent assay
Human Ab42 levels were determined using the enzyme-linked
immunosorbent assay (ELISA) detection kit from Life Technologies
(cat#KHB3442) following the speciﬁed instructions. Protein samples
from 14emonth-old mouse brains were diluted 1:50 in standard
diluent buffer to ensure that urea and sodium dodecyl sulfate levels
were compatible with the ELISA kit (see protein isolation details at
Section 2.3). Samples were then compared with a standard curve,
and Ab42 concentrations were established against the samples’
protein concentrations followingmanufacturer’s recommendations.
2.8. Statistical analysis
Data were analyzed using GraphPad Prism software. Signiﬁ-
cance was calculated using unpaired t tests for comparisons be-
tween 2 groups and 1-way multifactorial analysis of variance
followed by Tukey post hoc tests for multiple comparisons. p Values
are provided as stated by GraphPad, and signiﬁcance was deter-
mined with p values <0.05.
3. Results
Mice carrying only 1 copy of Meox2 (B6.Mx/þ mice, see
Section 2) were used to determine the contribution of Meox2
haploinsufﬁciency to AD-related pathology. Western blots
conﬁrmed that MEOX2 protein levels were reduced byw50% in the
brains of 4-month-old B6.Mx/þ mice compared with wild-type
controls (B6.Mxþ/þ, Fig. 1A). A previous study reported reductions
in cerebral microvessels and in cortical CBF in mice hap-
loinsufﬁcient for Meox2 (Wu et al., 2005). In line with these pre-
vious ﬁndings, we also found a small but signiﬁcant reduction in
CD31þ microvessels in our 4-month-old B6.Mx/þ mice compared
with B6 mice (Fig. 1B). However, in contrast to previous ﬁndings, no
differences in the number of cortical NEUNþ neurons were found
between 10-month-old-B6.Mx/þ and B6 mice (Fig. 1C), indicating
that in the strain used here, Meox2 haploinsufﬁciency alone does
not affect neuronal survival. Possible explanations for these differ-
ences include choice of Meox2 null allele and strain backgrounds.
3.1. Meox2 haploinsufﬁciency promotes Y-maze deﬁcits and
neuronal loss in B6.APBTg mice
Cohorts of at least 8 B6.APBTg.Mx/þ mice and similar numbers
of littermate controls (B6, B6.Mx/þ, and B6.APBTg) were estab-
lished and aged to 14 months, and spatial working memory was
examined using a Y-maze (Fig. 2A and B). At 14 months of age, a
signiﬁcant deﬁcit in spontaneous alternation was seen only in
B6.APBTg.Mx/þ mice (43.58%  7.75%, p ¼ 0.0183) and not in the
control strains (B6 ¼ 53.85%  6.99%, B6.APBTg ¼ 51.58%  8.03%,
and B6.Mx/þ ¼ 55.30%  6.43%). No differences in the number of
entries were found between groups (Fig. 2B). Mice were harvested
and neuronal cell loss assessed. NEUN-immunostained neurons
were quantiﬁed in the cortex and hippocampus of B6.APBTg.Mx/þ
mice and comparedwith controlmice. A signiﬁcant decrease in the
number of NEUNþ cells was found in both the cortex and hippo-
campus of 14-month-old B6.APBTg.Mx/þ mice compared with
control mice (Fig. 2CeF). Interestingly, neuronal cell loss was not
observed in a second cohort of 10-month-old B6.APBTg.Mx/þmice
(data not shown), suggesting that neuronal cell loss occurred
between 10 and 14 months of age.
Fig. 3. Meox2 haploinsufﬁciency does not alter amyloid-b (Ab) deposition in B6.APBTg.Mx/þ mice. (A) Western blot analysis of soluble amyloid precursor protein (APP) using 6E10
antibody shows no signiﬁcant differences between B6.APBTg and B6.APBTg.Mx/þ mice. (B) Quantitative analysis of Ab42 peptide by enzyme-linked immunosorbent assay shows no
signiﬁcant differences between B6.APBTg and B6.APBTg.Mx/þ mice. (C) Representative images and quantiﬁcation of Ab plaque deposition using ThioS staining showed no signiﬁcant
differences between B6.APBTg and B6.APBTg.Mx/þmice. (A and B) Values are mean  standard error of the mean, n ¼ 4 mice per group, ****p < 0.0001 by 1-way analysis of variance.
Scale bars: 500 mm (top panels) and 100 mm (bottom panels).
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3.2. Meox2 haploinsufﬁciency does not alter Ab production, plaque
deposition, or glia activation in B6.APBTg mice
To begin to determine the mechanism(s) through which Meox2
haploinsufﬁciency causes neuronal cell loss in B6.APBTg mice, pla-
que load was assessed in B6.APBTg.Mx/þ and B6.APBTg mice at both
10 and 14 months of age. Immunoblotting using 6E10, an antibody
that binds human APP protein and its fragments, showed no sig-
niﬁcant differences in human soluble APP levels between
B6.APBTg.Mx/þ and B6.APBTgmice (Fig. 3A). Similarly, no differences
were found in human Ab42 levels (by ELISA, Fig. 3B) or Ab plaque
load (by Thioﬂavin S [ThioS] staining, Fig. 3C) between brains of
B6.APBTg.Mx/þ and B6.APBTg mice, indicating that Meox2 hap-
loinsufﬁciency did not dramatically alter APP production or amyloid
deposition. Next, astrocyte reactivity andmicroglial activationwere
assessed. Astrocyte reactivity, assessed by GFAP immunostaining,
was signiﬁcantly increased in the cortex of B6.APBTg and
B6.APBTg.Mx/þmice at both 10 and 14months comparedwith B6 or
B6.Mx/þ mice (Fig. 4A and C). However, no differences in GFAP
immunostaining were found between B6.APBTg and B6.APBTg.Mx/þ
mice at both 10 and 14 months of age. Microglial activation was
assessed using IBA1, TREM2, and CD68 and was also not
signiﬁcantly different between B6.APBTg and B6.APBTg.Mx/þ mice
(Figs. 4B and D and 5). Collectively, these data suggest that glial cell
responses are not overtly different in B6.APBTg.Mx/þ compared
with B6.APBTg mice.
3.3. Reduced microvessel coverage surrounding plaques correlated
with increased neuronal cell loss in B6.APBTg.Mx/þ mice
Because Meox2 haploinsufﬁciency causes reductions in micro-
vessels from a young age (Fig. 1), we analyzed the area of micro-
vessels (using CD31, a marker of endothelial cells, see Section 2) in
the cortex and hippocampus (CA1 region) of B6.APBTg.Mx/þ and
control mice at 10 and 14 months of age (Fig. 6A). As expected, the
area of cortical and CA1 microvessels immunolabeled with CD31
was signiﬁcantly reduced in both B6.APBTg.Mx/þ and B6.Mx/þ
mice compared with B6 and B6.APBTgmice (Fig. 6B and C). However,
compared with B6.Mx/þ mice, B6.APBTg.Mx/þ showed a further
and signiﬁcant reduction in CD31þ microvessel area in the cortex
(but not in the CA1 region) (Fig. 6B and C) at 14 months of age. This
suggests additional loss of cortical microvessels in B6.APBTg.Mx/þ
mice compared with B6.Mx/þ mice.
Previous studies have shown that plaque deposition disrupts
microvessels (Brown and Thore, 2011; Grammas et al., 2011;
Kelleher and Soiza, 2013; Zlokovic, 2011). Therefore, we
Fig. 4. Meox2 haploinsufﬁciency does not alter glial activation in B6.APBTg.Mx/þ mice. (A) Representative images of glial ﬁbrillary acidic protein (GFAP) immunostaining of as-
trocytes in the cortex of B6, B6.APBTg, B6.Mx/þ, and B6.APBTg.Mx/þ mice at 14 months of age. (B) Representative images of IBA1 immunostaining of microglial cells in the cortex of
B6, B6.APBTg, B6.Mx/þ, and B6.APBTg.Mx/þ mice at 14 months of age. (C) Quantitative analysis of GFAP-immunolabeled area in the cortex of B6, B6.APBTg, B6.Mx/þ, and
B6.APBTg.Mx/þ mice at 10 and 14 months of age. Signiﬁcant increases in GFAP levels were observed B6.APBTg and B6.APBTg.Mx/þ mice compared with B6 or B6.Mx/þ mice. No
signiﬁcant differences were observed between B6.APBTg and B6.APBTg.Mx/þ mice. (D) Quantitative analysis of IBA1þ microglial cells in the cortex of B6, B6.APBTg, B6.Mx/þ, and
B6.APBTg.Mx/þ mice at 10 and 14 months of age. Signiﬁcant increases in IBA1þ cells were observed B6.APBTg and B6.APBTg.Mx/þ mice compared with B6 or B6.Mx/þ mice. No
signiﬁcant differences were observed between B6.APBTg and B6.APBTg.Mx/þ mice. (C and D) Values are mean  standard error of the mean, n ¼ 4 mice per group, **p < 0.01, ***p <
0.001, and ****p < 0.0001 by 1-way analysis of variance. Scale bars: 50 mm.
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hypothesized that microvessel loss in B6.APBTg.Mx/þ mice would
be greatest in regions containing plaques. To test this, brain sections
from B6.APBTg.Mx/þ and controls at 14 months of age were
immunolabeled with LAMA2, a basement membrane protein that
identiﬁes microvessels, and lectin, a protein that binds to cell
membranes and conveniently labels microvessels (Mazzetti et al.,
2004). In addition, strong immunoreactivity of lectin was found in
microglia clusters surrounding the amyloid plaques (Fig. 7A and 8A)
and when combined with LAMA2 allows simultaneous assessment
of microvessel and plaque area (see Section 2). There was no sig-
niﬁcant difference in the area of LAMA2þ microvessels in B6.APBTg
mice compared with B6 mice (Fig. 8B). However, a signiﬁcant
reduction in LAMA2þ microvessel area surrounding plaques was
found in B6.APBTg.Mx/þ mice compared with B6.APBTg mice
(Fig. 8B). This difference was not because of changes in plaque size
(Fig. 8C). We next determined whether the combination of micro-
vessel reduction and plaque deposition in B6.APBTg.Mx/þ mice
could be intensifying the loss of neurons in B6.APBTg.Mx/þ
compared with control mice. NEUNþ neurons were quantiﬁed
speciﬁcally in regions of activated IBA1þ microglia clusters sur-
rounding plaques (Fig. 8D). There was a signiﬁcant reduction in
NEUNþ neurons surrounding plaques in B6.APBTg.Mx/þ mice
Fig. 5. Microglia are not overtly affected by Meox2 haploinsufﬁciency. (A) Representative images of colocalization of CD68 and TREM2 with allograft inﬂammatory factor 1þ
microglial cells in B6.APBTg and B6.APBTg.Mx/þmice. (B) Quantitative analyses of TREM2 and CD68 immunostained area in B6.APBTg and B6.APBTg.Mx/þmice at 14 months of age. No
signiﬁcant differences were found between groups. (B) Values are mean  standard error of the mean, n ¼ 4 mice per group. Scale bar: 50 mm.
I. Soto et al. / Neurobiology of Aging 42 (2016) 50e6056
compared with B6.APBTg mice (Fig. 8E), which was independent of
plaque area (Fig. 8F). Therefore, Meox2 haploinsufﬁciency and
plaque deposition had a synergistic neurotoxic effect in
B6.APBTg.Mx/þ mice.
4. Discussion
It is thought that pathologic neurovascular irregularities and
vascular risk factors are important contributors to the onset and
progression of AD. Several reports have shown severe pathologic
changes in the cerebral vasculature (Buee et al., 1994; Farkas and
Luiten, 2001; Grammas, 2011; Halliday et al., 2015; Sagare et al.,
2012; Zlokovic, 2005) and associated vascular-related genetic risk
factors (Bell, 2012; Winkler et al., 2015; Zhao et al., 2015; Zlokovic,
2010) with AD development and progression. Vascular-related
genes have been found to be both affected by AD (e.g., GLUT1 and
LRP) and identiﬁed as genetic risk factors for disease development
(e.g., APOE, MEOX2, MYOCD, and PICALM) (Bell, 2012; Mahley et al.,
2009; Sagare et al., 2012; Zlokovic, 2010). In the case of MEOX2,
rare copy number variants for this gene are associated with a severe
form of AD in humans (Rovelet-Lecrux et al., 2012). Furthermore,
MEOX2 expression is downregulated in endothelial cells frombrains
Fig. 6. Meox2 haploinsufﬁciency induces endothelial cell loss in B6.APBTg.Mx/þ mice. (A) Representative images of CD31-immunolabeled endothelial cells in the cortex and hip-
pocampal CA1. (B) Quantitative analysis of CD31þ microvessel length in the cortex of B6, B6.APBTg, B6.Mx/þ, and B6.APBTg.Mx/þ mice at 10 and 14 months of age. (C) Quantitative
analysis of CD31þmicrovessel length in the hippocampal CA1 at 10 and 14 months of age. (B and C) Values are mean  standard error of the mean, n ¼ 4 mice per group, *p < 0.05,
**p < 0.01, and ***p < 0.001 by 1-way analysis of variance. Scale bars: 50 mm in (A).
Fig. 7. ThioSþ plaques are also identiﬁed by lectin that marks microglial clusters. ThioSþ plaque (magenta) is immunostained by lectin (blue). Scale bar: 50 mm.
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of AD patient, and these cells were found to be dysfunctional and
pro-apoptotic in in vitro assays of vascular tube formation (Wu et al.,
2005). In addition, previous studies (Wu et al., 2005), conﬁrmed in
our study here (Fig. 1), showed that haploinsufﬁciency of MEOX2 in
mice led to microvascular reductions in the brain. Given the asso-
ciation of copy number variations ofMEOX2with severe forms of AD
(Rovelet-Lecrux et al., 2012), this suggests MEOX2-mediated
vascular dysfunction may be a contributing factor in AD. In
support of this, here we show that haploinsufﬁciency of Meox2 in
mice reduces cerebral vascular density and leads to neuronal loss
and cognitive deﬁcits in B6.APBTg mice.
Interestingly, no changes in plaque load or deposition were
found between B6.APBTg.Mx/þ and B6.APBTg mice, indicating that
Meox2 haploinsufﬁciency in combination with plaque load caused
an age-dependent degeneration of neurons in B6.APBTg.Mx/þmice.
Several mouse models of AD have successfully shown extensive
Fig. 8. Loss of microvessels in B6.APBTg.Mx/þ mice is more severe in plaque regions. (A) Representative images of dual immunolabeling of microvessels with laminin A2 (LAMA2)
(green) and lectin (blue) in B6.APBTg and B6.APBTg.Mx/þ mice. Lectin is also labeling plaque clusters (see also Fig. 7). (B) Quantitative analysis of LAMA2-immunolabeled area
showing a signiﬁcant reduction of microvessels in regions containing plaques in B6.APBTg.Mx/þmice compared with B6.APBTg mice at 14 months of age. (C) Quantitative analysis of
lectinþ area in B6.APBTg and B6.APBTg.Mx/þ mice at 14 months of age. (D) Representative images of dual immunolabeling of neurons with NEUN (red) and plaque-associated
microglia (green) with IBA1 in B6.APBTg and B6.APBTg.Mx/þ mice. (E) Quantitative analysis of NEUN-immunolabeled neurons showing a signiﬁcant reduction of these cells in
B6.APBTg.Mx/þ mice at 14 months of age. (F) Quantitative analysis of IBA1þ plaque cluster area in B6.APBTg and B6.APBTg.Mx/þ mice at 14 months of age. (B, C, E, and F) Values are
mean  standard error of the mean, n ¼ 4 mice per group, *p < 0.05, **p < 0.01, and ****p < 0.0001 by 1-way analysis of variance. (F) ****p < 0.0001 by unpaired t test. Scale bars:
50 mm.
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amyloid plaque deposition and neuroinﬂammation, but, in the
absence of additional genetic manipulations, not many show sig-
niﬁcant neuronal loss and associated cognitive decline (Onos et al.,
2015; Webster et al., 2014; Wirths and Bayer, 2010). The lack of
substantial neuronal cell loss signiﬁcantly limits the identiﬁcation
and testing of therapeutic targets for AD (Onos et al., 2015). How-
ever, recent studies have shown that combinatorial approaches that
disrupt neurovascular function in addition to promoting Ab plaque
deposition can induce neuronal cell loss and some cognitive
impairment (Sagare et al., 2013; Winkler et al., 2015; Zhao et al.,
2015). In our study, Meox2 haploinsufﬁciency caused early re-
ductions in microvessel density that did not promote neuronal loss
(Fig. 1). However, when combined with mutant APP and PSEN1
proteins, Meox2 haploinsufﬁciency caused signiﬁcant neuronal loss
(Fig. 2), particularly around plaques (Fig. 8). Interestingly, micro-
vessel reduction and plaque deposition occurred before neuronal
cell loss in B6.APBTg.Mx/þmice suggesting microvessel deﬁciencies
and amyloid deposition combine to cause neuronal cell loss in this
model.
It is not clear why Meox2 haploinsufﬁciency causes increased
neuronal cell loss in B6.APBTg.Mx/þ mice compared with B6.APBTg
mice. One explanation may lie in the fact that Meox2 hap-
loinsufﬁciency causes signiﬁcant reductions in CBF causing hypo-
perfusion (Wu et al., 2005). It is possible that hypoperfusion in
B6.APBTg.Mx/þ compared with B6.APBTg mice sensitizes neurons to
Ab toxicity, as a mild reduction in CBF can disrupt important
neuronal functions, such as protein synthesis (Iadecola, 2004;
Zlokovic, 2011). Furthermore, it is possible that CBF could be even
more compromised in B6.APBTg.Mx/þ mice because of the deposi-
tionofAb, leading to an additional loss ofmicrovessels and increased
neuronal toxicity. An alternative explanation is that decreased levels
ofMeox2 in endothelial cells may disrupt Ab clearance. Ab is cleared
by the vascular system through the low-density lipoprotein 1 (LRP1)
receptor. Reduced levels of LRP1 receptor as a result of microvessel
loss would result in potential accumulation of Ab on blood vessels
(Wu et al., 2005; Zlokovic, 2010; Zlokovic et al., 2010). Although in
our study, we saw no signiﬁcant differences in overall plaque load
between B6.APBTg.Mx/þ and B6.APBTg mice; therefore, this expla-
nation seems unlikely. However, given that neurons are the main
producers of mutant human APP in the mouse model used here
(Borchelt et al., 1997), it is possible that B6.APBTg.Mx/þ has an
increased ratio of APP productionper neuron aswedid notobserve a
decrease in APP levels (Fig. 3A) despite observing neuronal cell loss
(Fig. 2). Interestingly, by considering the ratio of plaque load to APP-
producing neuronal cell number between B6.APBTg and
B6.APBTg.Mx/þmice, we can propose that B6.APBTg.Mx/þmice had
increased plaque load compared with B6.APBTg mice. Although
further investigation is required, this suggests that clearance of Ab
may be affected by Meox2 haploinsufﬁciency. Irrespective of the
mechanism bywhichMeox2 haploinsufﬁciency causes neuronal cell
loss, we propose it creates a more human-relevant environment.
MEOX2 expression is downregulated in endothelial cells in human
AD brains (Wu et al., 2005), whereasMeox2 is not downregulated in
endothelial cells during disease progression in mouse models of AD
where neuronal cell loss is not normally observed. This lack of a
reduction in MEOX2 protein in mouse models of AD may cause a
robustness ofmouse cerebral endothelial cells in response to plaque
load and override the neurotoxic effects of Ab plaque deposition
observed in humans (Deshpande et al., 2006; Donev et al., 2009;
Urbanc et al., 2002; Yankner et al., 1989). This robustness could be
lessened by Meox2 haploinsufﬁciency, causing further loss of
vascular endothelial cells and neurons in these plaque regions. This
mechanism could also account for the association between copy
number variations involving MEOX2 with severe phenotypes in
human AD (Rovelet-Lecrux et al., 2012).
The reduction in vascular density in the brain caused by a
combination of Meox2 haploinsufﬁciency and Ab deposition could
be an important contributor to cerebral hypoperfusion in AD
(Brown and Thore, 2011; Farkas and Luiten, 2001; Grammas, 2011;
Zlokovic, 2005). Cerebral hypoperfusion has been considered a
major contributor to cognitive impairment and AD development
and pathology. CBF has been seen to be reduced in the initial stages
of AD when early cognitive impairment is detected, which suggests
that vascular dysfunction precedes neuronal degeneration and
brain atrophy (Hirao et al., 2005; Johnson et al., 2005; Pakrasi and
O’Brien, 2005). One possible mechanism is that decreased CBF
and altered uptake and utilization of glucose and oxygen (Brown
and Thore, 2011; Farkas and Luiten, 2001; Grammas, 2011;
Zlokovic, 2005) can lead to impairments in neuronal metabolism
and function (Farkas and Luiten, 2001; Hermann et al., 2001;
Zlokovic, 2011) causing cognitive decline and neurodegeneration.
In conclusion, our study shows that Meox2 haploinsufﬁciency
mediates amyloid dependent neuronal cell loss and Y-maze deﬁcits,
possibly by effecting microvessels surrounding plaques. Hence,
therapies that include preservation of microvessels should be
considered for human AD.
Disclosure statement
The authors have no conﬂicts of interest to disclose.
Acknowledgements
The authors would like to thank Kelly Keezer and Keating Pepper
for help with mouse breeding and maintenance and Stacey Rizzo
and members of the Mouse Neurobehavioral Phenotyping Facility
at The Jackson Laboratory. This work was funded in part by The
Jackson Laboratory Nathan Shock Center for Excellence in the Basic
Biology of Aging, the Fraternal Order of the Eagle, the Jane B. Cook
Foundation, and National Institutes of Health (NIH) R01 EY021525
(G.R.H.). W.A.G. was supported by an Institutional Development
Award (IDeA) from the National Institute of General Medical Sci-
ences of the NIH under grant number P20GM103423. The authors
declare no competing ﬁnancial interests.
References
Bell, R.D., 2012. The imbalance of vascular molecules in Alzheimer’s disease.
J. Alzheimers Dis. 32, 699e709.
Bertholet, J.Y., Crusio, W.E., 1991. Spatial and non-spatial spontaneous alternation
and hippocampal mossy ﬁbre distribution in nine inbred mouse strains. Behav.
Brain Res. 43, 197e202.
Borchelt, D.R., Ratovitski, T., van Lare, J., Lee, M.K., Gonzales, V., Jenkins, N.A.,
Copeland, N.G., Price, D.L., Sisodia, S.S., 1997. Accelerated amyloid deposition in
the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid
precursor proteins. Neuron 19, 939e945.
Brown, W.R., Thore, C.R., 2011. Review: cerebral microvascular pathology in ageing
and neurodegeneration. Neuropathol. Appl. Neurobiol. 37, 56e74.
Buee, L., Hof, P.R., Bouras, C., Delacourte, A., Perl, D.P., Morrison, J.H., Fillit, H.M.,
1994. Pathological alterations of the cerebral microvasculature in Alzheimer’s
disease and related dementing disorders. Acta Neuropathol. 87, 469e480.
Deshpande, A., Mina, E., Glabe, C., Busciglio, J., 2006. Different conformations of
amyloid beta induce neurotoxicity by distinct mechanisms in human cortical
neurons. J. Neurosci. 26, 6011e6018.
Dewey, M.E., Saz, P., 2001. Dementia, cognitive impairment and mortality in persons
aged 65 and over living in the community: a systematic review of the literature.
Int. J. Geriatr. Psychiatry 16, 751e761.
Donev, R., Kolev, M., Millet, B., Thome, J., 2009. Neuronal death in Alzheimer’s
disease and therapeutic opportunities. J. Cell Mol. Med. 13, 4329e4348.
Drew, W.G., Miller, L.L., Baugh, E.L., 1973. Effects of delta9-THC, LSD-25 and
scopolamine on continuous, spontaneous alternation in the Y-maze. Psycho-
pharmacologia 32, 171e182.
Farkas, E., Luiten, P.G., 2001. Cerebral microvascular pathology in aging and
Alzheimer’s disease. Prog. Neurobiol. 64, 575e611.
Gorski, D.H., Walsh, K., 2003. Control of vascular cell differentiation by homeobox
transcription factors. Trends Cardiovasc. Med. 13, 213e220.
I. Soto et al. / Neurobiology of Aging 42 (2016) 50e60 59
Grammas, P., 2011. Neurovascular dysfunction, inﬂammation and endothelial acti-
vation: implications for the pathogenesis of Alzheimer’s disease.
J. Neuroinﬂammation 8, 26.
Grammas, P., Tripathy, D., Sanchez, A., Yin, X., Luo, J., 2011. Brain microvasculature
and hypoxia-related proteins in Alzheimer’s disease. Int. J. Clin. Exp. Pathol. 4,
616e627.
Halliday, M.R., Rege, S.V., Ma, Q., Zhao, Z., Miller, C.A., Winkler, E.A., Zlokovic, B.V.,
2015. Accelerated pericyte degeneration and blood-brain barrier breakdown in
apolipoprotein E4 carriers with Alzheimer’s disease. J. Cereb. Blood Flow Metab.
36, 216e227.
Hermann, D.M., Kilic, E., Hata, R., Hossmann, K.A., Mies, G., 2001. Relationship be-
tween metabolic dysfunctions, gene responses and delayed cell death after mild
focal cerebral ischemia in mice. Neuroscience 104, 947e955.
Hirao, K., Ohnishi, T., Hirata, Y., Yamashita, F., Mori, T., Moriguchi, Y., Matsuda, H.,
Nemoto, K., Imabayashi, E., Yamada, M., Iwamoto, T., Arima, K., Asada, T., 2005.
The prediction of rapid conversion to Alzheimer’s disease in mild cognitive
impairment using regional cerebral blood ﬂow SPECT. Neuroimage 28,
1014e1021.
Hooper, N., Fraser, C., Stone, T.W., 1996. Effects of purine analogues on spontaneous
alternation in mice. Psychopharmacology (Berl) 123, 250e257.
Hughes, R.N., 2004. The value of spontaneous alternation behavior (SAB) as a test of
retention in pharmacological investigations of memory. Neurosci. Biobehav.
Rev. 28, 497e505.
Iadecola, C., 2004. Neurovascular regulation in the normal brain and in Alzheimer’s
disease. Nat. Rev. Neurosci. 5, 347e360.
Jacquelin, C., Strazielle, C., Lalonde, R., 2012. Spontaneous alternation and spatial
learning in Dab1scm (scrambler) mutant mice. Brain Res. Bull. 87, 383e386.
Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N.A.,
Copeland, N.G., Lee, M.K., Younkin, L.H., Wagner, S.L., Younkin, S.G.,
Borchelt, D.R., 2004. Mutant presenilins speciﬁcally elevate the levels of the 42
residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-spe-
ciﬁc gamma secretase. Hum. Mol. Genet. 13, 159e170.
Johnson, N.A., Jahng, G.H., Weiner, M.W., Miller, B.L., Chui, H.C., Jagust, W.J., Gorno-
Tempini, M.L., Schuff, N., 2005. Pattern of cerebral hypoperfusion in Alzheimer
disease and mild cognitive impairment measured with arterial spin-labeling
MR imaging: initial experience. Radiology 234, 851e859.
Kelleher, R.J., Soiza, R.L., 2013. Evidence of endothelial dysfunction in the develop-
ment of Alzheimer’s disease: is Alzheimer’s a vascular disorder? Am. J. Car-
diovasc. Dis. 3, 197e226.
Knopman, D.S., Roberts, R., 2010. Vascular risk factors: imaging and neuropathologic
correlates. J. Alzheimers Dis. 20, 699e709.
Mahley, R.W., Weisgraber, K.H., Huang, Y., 2009. Apolipoprotein E: structure de-
termines function, from atherosclerosis to Alzheimer’s disease to AIDS. J. Lipid
Res. 50 (Suppl), S183eS188.
Mazzetti, S., Frigerio, S., Gelati, M., Salmaggi, A., Vitellaro-Zuccarello, L., 2004.
Lycopersicon esculentum lectin: an effective and versatile endothelial marker of
normal and tumoral blood vessels in the central nervous system. Eur. J. Histo-
chem. 48, 423e428.
Norton, S., Matthews, F.E., Barnes, D.E., Yaffe, K., Brayne, C., 2014. Potential for pri-
mary prevention of Alzheimer’s disease: an analysis of population-based data.
Lancet Neurol. 13, 788e794.
Onos, K.D., Sukoff Rizzo, S.J., Howell, G.R., Sasner, M., 2015. Toward more predictive
genetic mouse models of Alzheimer’s disease. Brain Res. Bull. 122, 1e11.
Pakrasi, S., O’Brien, J.T., 2005. Emission tomography in dementia. Nucl. Med. Com-
mun. 26, 189e196.
Rovelet-Lecrux, A., Legallic, S., Wallon, D., Flaman, J.M., Martinaud, O., Bombois, S.,
Rollin-Sillaire, A., Michon, A., Le Ber, I., Pariente, J., Puel, M., Paquet, C.,
Croisile, B., Thomas-Anterion, C., Vercelletto, M., Levy, R., Frebourg, T.,
Hannequin, D., Campion, D.Investigators of the GMAJ Project, 2012. A genome-
wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer
disease. Eur. J. Hum. Genet. 20, 613e617.
Sagare, A.P., Bell, R.D., Zhao, Z., Ma, Q., Winkler, E.A., Ramanathan, A., Zlokovic, B.V.,
2013. Pericyte loss inﬂuences Alzheimer-like neurodegeneration in mice. Nat.
Commun. 4, 2932.
Sagare, A.P., Bell, R.D., Zlokovic, B.V., 2012. Neurovascular dysfunction and faulty
amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb. Per-
spect. Med. 2, a011452.
Sengillo, J.D., Winkler, E.A., Walker, C.T., Sullivan, J.S., Johnson, M., Zlokovic, B.V.,
2013. Deﬁciency in mural vascular cells coincides with blood-brain barrier
disruption in Alzheimer’s disease. Brain Pathol. 23, 303e310.
Soto, I., Graham, L.C., Richter, H.J., Simeone, S.N., Radell, J.E., Grabowska, W.,
Funkhouser, W.K., Howell, M.C., Howell, G.R., 2015. Apoe stabilization by exer-
cise prevents aging neurovascular dysfunction and complement induction. PLoS
Biol. 13, e1002279.
Urbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K.H., Duff, K., Stanley, H.E., Irizarry, M.C.,
Hyman, B.T., 2002. Neurotoxic effects of thioﬂavin S-positive amyloid deposits
in transgenic mice and Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 99,
13990e13995.
Webster, S.J., Bachstetter, A.D., Nelson, P.T., Schmitt, F.A., Van Eldik, L.J., 2014. Using
mice to model Alzheimer’s dementia: an overview of the clinical disease and
the preclinical behavioral changes in 10 mouse models. Front Genet. 5, 88.
Winkler, E.A., Nishida, Y., Sagare, A.P., Rege, S.V., Bell, R.D., Perlmutter, D., Sengillo, J.D.,
Hillman, S., Kong, P., Nelson, A.R., Sullivan, J.S., Zhao, Z., Meiselman, H.J.,
Wenby, R.B., Soto, J., Abel, E.D., Makshanoff, J., Zuniga, E., De Vivo, D.C.,
Zlokovic, B.V., 2015. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-
neuronal dysfunction and degeneration. Nat. Neurosci. 18, 521e530.
Wirths, O., Bayer, T.A., 2010. Neuron loss in transgenic mouse models of Alzheimer’s
disease. Int. J. Alzheimers Dis. http://dx.doi.org/10.4061/2010/723782.
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R.D., Deane, R., Brooks, A.I., Kanagala, S.,
Rubio, A., Sagare, A., Liu, D., Li, F., Armstrong, D., Gasiewicz, T., Zidovetzki, R.,
Song, X., Hofman, F., Zlokovic, B.V., 2005. Role of the MEOX2 homeobox gene in
neurovascular dysfunction in Alzheimer disease. Nat. Med. 11, 959e965.
Yankner, B.A., Dawes, L.R., Fisher, S., Villa-Komaroff, L., Oster-Granite, M.L.,
Neve, R.L., 1989. Neurotoxicity of a fragment of the amyloid precursor associated
with Alzheimer’s disease. Science 245, 417e420.
Zhao, Z., Sagare, A.P., Ma, Q., Halliday, M.R., Kong, P., Kisler, K., Winkler, E.A.,
Ramanathan, A., Kanekiyo, T., Bu, G., Owens, N.C., Rege, S.V., Si, G., Ahuja, A.,
Zhu, D., Miller, C.A., Schneider, J.A., Maeda, M., Maeda, T., Sugawara, T.,
Ichida, J.K., Zlokovic, B.V., 2015. Central role for PICALM in amyloid-beta blood-
brain barrier transcytosis and clearance. Nat. Neurosci. 18, 978e987.
Zlokovic, B.V., 2005. Neurovascular mechanisms of Alzheimer’s neurodegeneration.
Trends Neurosci. 28, 202e208.
Zlokovic, B.V., 2010. Neurodegeneration and the neurovascular unit. Nat. Med. 16,
1370e1371.
Zlokovic, B.V., 2011. Neurovascular pathways to neurodegeneration in Alzheimer’s
disease and other disorders. Nat. Rev. Neurosci. 12, 723e738.
Zlokovic, B.V., Deane, R., Sagare, A.P., Bell, R.D., Winkler, E.A., 2010. Low-density
lipoprotein receptor-related protein-1: a serial clearance homeostatic mecha-
nism controlling Alzheimer’s amyloid beta-peptide elimination from the brain.
J. Neurochem. 115, 1077e1089.
I. Soto et al. / Neurobiology of Aging 42 (2016) 50e6060
